Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Achten, Roselie; Bakker, Daphne; Luijk, Chantal M. van; Wal, Marlot van der; Graaf, Marlies de; Wijk, Femke van; Zuithoff, Nicolaas P.A.; Rijst, Lisa P van der; Boesjes, Celeste M; Thijs, Judith L.; Boer, Joke de; Bruin‐Weller, Marjolein de

doi:10.1111/cea.14127

Cited by 15 publications

(44 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIC was obtained as described previously, and stored in 100 µL PBS (Sigma) at −80°C until further analysis. 7 LC‐MS/MS was used to measure dupilumab in CIC suspensions.…”

Section: Data Collectionmentioning

confidence: 99%

“…Conjunctival impression cytology (CIC) was collected from 3 control AD patients (not treated with dupilumab) and from 5 AD patients treated with dupilumab for 4 weeks. CIC was obtained as described previously, and stored in 100 µL PBS (Sigma) at −80°C until further analysis 7 . LC‐MS/MS was used to measure dupilumab in CIC suspensions.…”

Section: Data Collectionmentioning

confidence: 99%

“…Remarkably, in dupilumab trials in other type‐2 inflammatory diseases, such as asthma and chronic rhinosinusitis with nasal polyposis, no increased rates of DAOSD were reported 6 . Recently we found that 90% of the moderate‐to‐severe AD patients had clinical characteristics of ocular surface disease (OSD) before the start of dupilumab, suggesting that AD patients may have a predisposition to develop DAOSD 7 . It might be possible that this pre‐existent OSD is aggravated during dupilumab treatment and is then diagnosed as DAOSD.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Recently we found that 90% of the moderate‐to‐severe AD patients had clinical characteristics of ocular surface disease (OSD) before the start of dupilumab, suggesting that AD patients may have a predisposition to develop DAOSD. 7 It might be possible that this pre‐existent OSD is aggravated during dupilumab treatment and is then diagnosed as DAOSD.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Achten

Thijs

Wal

et al. 2023

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

Background:The patho-mechanism of ocular surface disease (OSD) in dupilumabtreated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients.Methods: This prospective study included dupilumab-treated moderate-to-severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and after 4 and 28 weeks of dupilumab treatment.Dupilumab levels in tear fluid and serum were measured by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Additionally, a pilot study was conducted to measure dupilumab on conjunctival epithelial cells using flow cytometry and LC-MS/MS.Results: At baseline, 89.6% (n = 43/48) of the patients had OSD, with 50.0% having moderate-to-severe OSD. After 28 weeks of dupilumab treatment, the median dupilumab tear fluid levels were 0.55 mg/L (IQR 0.35-1.31) and 0.29 mg/L (IQR 0.16-0.60) in patients with moderate-to-severe OSD and patients with no or mild OSD, respectively (p = 0.02). Dupilumab levels could be detected on conjunctival epithelial cells of 5 AD patients treated with dupilumab for 4 weeks. Conclusion:Patients with moderate-to-severe OSD had higher dupilumab tear fluid levels compared to patients with no or mild OSD, indicating that dupilumab reaches the ocular surface. Dupilumab was also detected in conjunctival cell suspensions and was found to directly bind CD45-conjunctival epithelial cells. This suggests that ADinduced changes of the conjunctival epithelium may play a role in the development of OSD as well as increased local drug availability.

show abstract

“…CIC was obtained as described previously, and stored in 100 µL PBS (Sigma) at −80°C until further analysis. 7 LC‐MS/MS was used to measure dupilumab in CIC suspensions.…”

Section: Data Collectionmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Achten

Thijs

Wal

et al. 2023

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, physicians should not be reluctant to prescribe anti‐inflammatory ophthalmic medication. As we recently described that 90% of moderate‐to‐severe AD patients already have OSD before starting treatment, it is important to monitor patients ophthalmologically from the start of treatment with dupilumab or tralokinumab in order to distinguish between DAOSD/TAOSD and AD‐associated OSD 6 …”

Section: Dupilumab Treatment Tralokinumab Treatment Baseline Week 28 ...mentioning

confidence: 99%

Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Achten

Dekkers

Bakker

et al. 2023

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

et al. 2023

View full text Add to dashboard Cite

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Abstract: How to cite this article: Achten RE, Bakker DS, van Luijk CM, et al. Ocular surface disease is common in moderate-tosevere atopic dermatitis patients.

Cited by 15 publications

References 10 publications

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

Contact Info

Product

Resources

About